Insider · CIK 0001883840

RA Capital Nexus Fund III, L.P.

CIK 0001883840 Name as filed on the most recent filing

Filed as RA Capital Nexus Fund III, L.P. (29)

96 transaction lines · from 29 filings · filed 2023-02-16 to 2026-08-14 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-08-12 S, Open-market sale Septerna, Inc.SEPN 2 lines 63,452,500, disposed Open Form 4 filing 0001231919-26-000938
2026-07-31 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 247,694, acquired Open Form 4 filing 0001231919-26-000817
2026-07-29 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 208,032, acquired Open Form 4 filing 0001231919-26-000817
2026-07-24 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 412,777, acquired Open Form 4 filing 0001231919-26-000808
2026-07-23 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 596,405, acquired Open Form 4 filing 0001231919-26-000791
2026-07-22 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 835,351, acquired Open Form 4 filing 0001231919-26-000791
2026-07-22 P, Open-market purchase Parabilis Medicines, Inc.PBLS 1,406,633, acquired Open Form 4 filing 0001231919-26-000779
2026-07-21 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 1,151,558, acquired Open Form 4 filing 0001231919-26-000791
2026-07-21 P, Open-market purchase Parabilis Medicines, Inc.PBLS 3 lines 1,928,032, acquired Open Form 4 filing 0001231919-26-000779
2026-07-20 P, Open-market purchase Parabilis Medicines, Inc.PBLS 2 lines 3,584,887, acquired Open Form 4 filing 0001231919-26-000779
2026-07-17 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 70,544, acquired Open Form 4 filing 0001231919-26-000774
2026-07-16 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 1,361,575, acquired Open Form 4 filing 0001231919-26-000774
2026-07-13 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 58,307, acquired Open Form 4 filing 0001231919-26-000790
2026-07-13 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 58,575, acquired Open Form 4 filing 0001231919-26-000764
2026-07-10 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 135,465, acquired Open Form 4 filing 0001231919-26-000764
2026-06-26 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 16,846, acquired Open Form 4 filing 0001231919-26-000711
2026-06-25 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 275,280, acquired Open Form 4 filing 0001231919-26-000711
2026-06-16 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 1,110,299, acquired Open Form 4 filing 0001231919-26-000656
2026-06-15 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 138,572, acquired Open Form 4 filing 0001231919-26-000656
2026-06-12 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 3,351,033, acquired Open Form 4 filing 0001231919-26-000656
2026-06-11 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 4,339,268, acquired Open Form 4 filing 0001231919-26-000625
2026-06-11 P, Open-market purchase Parabilis Medicines, Inc.PBLS 2 lines 423,775,000, acquired Open Form 4 filing 0001231919-26-000638
2026-06-10 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 721, acquired Open Form 4 filing 0001231919-26-000625
2026-06-09 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 3,310,159, acquired Open Form 4 filing 0001231919-26-000625
2026-05-11 P, Open-market purchase Artiva Biotherapeutics, Inc.ARTV 74,999,992, acquired Open Form 4 filing 0001231919-26-000491
2026-03-30 P, Open-market purchase Mineralys Therapeutics, Inc.MLYS 1,408,528, acquired Open Form 4 filing 0001231919-26-000300
2026-03-27 P, Open-market purchase Mineralys Therapeutics, Inc.MLYS 7,354,269, acquired Open Form 4 filing 0001231919-26-000300
2026-02-26 P, Open-market purchase Bicara Therapeutics Inc.BCAX 4,800,000, acquired Open Form 4 filing 0001231919-26-000231
2026-02-09 P, Open-market purchase SpyGlass Pharma, Inc.SGP 2 lines 59,040,000, acquired Open Form 4 filing 0001231919-26-000135
2026-01-05 P, Open-market purchase Climb Bio, Inc.CLYM 24,889, acquired Open Form 4 filing 0001231919-26-000018
2025-12-12 P, Open-market purchase Climb Bio, Inc.CLYM 290,181, acquired Open Form 4 filing 0001231919-25-000616
2025-12-11 P, Open-market purchase Climb Bio, Inc.CLYM 464,556, acquired Open Form 4 filing 0001231919-25-000616
2025-11-21 S, Open-market sale Sionna Therapeutics, Inc.SION 4 lines 994,729, disposed Open Form 4 filing 0001231919-25-000547
2025-11-20 S, Open-market sale Sionna Therapeutics, Inc.SION 8 lines 205,975, disposed Open Form 4 filing 0001231919-25-000547

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. RA Capital Nexus Fund III, L.P., insider transactions. Retrieved 2026-08-23 from https://ebomi.com/insider/0001883840

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.